J. Du[1,2], L. Jin[1], W. Qiang[1], P. Guo[1], H. He[1], X. Fan[1], X. Zhao[1], D. Yuan[3], Y. Luo[3], and Z. Li[3]
[1] Department of Hematology, Myeloma & Lymphoma Center, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.
[2] Department of Hematology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
[3] CARsgen Ther.4)2letc (,)2.5 . LTt, Shanghai Chna.

CT0596

To evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of CT0596 in a first-in-human (FIH), open-label, single center, phase I study in relapsed/refractory multiple myeloma (RR MM) and plasma cell leukemia (PCL) patients (NCT06718270).

Eligibility:
- Age: ≥18 years;
- Patients with R/R MM had received at least 3 prior lines of therapy. Patients with R/R pPCL had received at least 1 prior line of therapy.
- MM patients have progressive disease following or during the last treatment.
- Patients must have measurable disease.
- ECOG score 0-1.

Dose levels (i3+3 escalating scheme): 1.5×10^8, 3.0×10^8 and 4.5×10^8 CT0596 cells.

Corresponding author: Juan Du

Tel. +86 13962191404; **Email:** juan_du@live.com

Preliminary results of this FIH study of CT0596, an allogeneic CAR T-cell therapy targeting BCMA for the treatment of RRMM, demonstrate a manageable safety profile while achieving durable clinical responses. Additional clinical studies are warranted to further evaluate the clinical utility of CT0596.